CDER Releases Updated Policies Manual on Proprietary Naming of Drugs
To reduce medication errors, CDER on Friday released its revised policies and procedures on proprietary naming of drugs, which are sometimes misidentified because of the way they are spelled or how the names sound.
The MAPP was originally released in September 2009, and this marks the first time the document has been revised. It includes new office names and updates responsibilities and procedures. It also describes procedures that may be submitted for INDS, NDAs, BLAs, efficacy or labeling supplements, and/or ANDA. It also includes FDA’s review performance goals about the naming of drugs.
The FDA says the update is important to help eliminate unclear label abbreviations, acronyms and dose designations, as well as label and packaging designs that can lead to user confusion.
The agency outlined a timetable for the review process, decision-making and performance goals and approvals through various FDA divisions — depending on the applications.
The Proprietary Name Review process starts when the Office of Surveillance and Epidemiology receives a proposed proprietary name submission, and then leads the overall review, seeking advice from other CDER offices as appropriate.
Overall, the OSE’s obligation is to:
Read the new MAPP here: www.fdanews.com/01-08-16-MAPP.pdf. — Joe Cantlupe
Subscribe to Drug Industry Daily and save $300 off the regular one-year price of $1,695 — plus receive a FREE copy of our webinar CD, Observational Studies — a $287 Value!
LINKS TO KEY DOCUMENTS — You get links to key documents that support DID's articles such as draft and final guidances, 483s and warning letters, proposed rules, closeout letter, full text of proposed legislation and GAO reports.
ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.
Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing